Wells Fargo Begins Coverage on Uniqure (QURE)

Wells Fargo started coverage on shares of Uniqure (NASDAQ:QURE) in a research note issued to investors on Wednesday morning, MarketBeat reports. The brokerage issued an outperform rating and a $47.00 price objective on the biotechnology company’s stock.

A number of other equities research analysts have also recently commented on QURE. HC Wainwright set a $35.00 target price on shares of Uniqure and gave the company a buy rating in a report on Tuesday, May 1st. BidaskClub upgraded shares of Uniqure from a buy rating to a strong-buy rating in a research note on Monday, May 14th. ValuEngine upgraded shares of Uniqure from a buy rating to a strong-buy rating in a research note on Wednesday, May 2nd. Chardan Capital reiterated a buy rating on shares of Uniqure in a research note on Monday, April 30th. Finally, Leerink Swann reiterated an outperform rating and set a $63.00 price target (up from $26.00) on shares of Uniqure in a research note on Monday, May 7th. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the stock. Uniqure presently has an average rating of Buy and a consensus price target of $30.88.

Shares of NASDAQ:QURE opened at $31.31 on Wednesday. Uniqure has a one year low of $4.90 and a one year high of $33.33. The company has a debt-to-equity ratio of 0.16, a current ratio of 5.48 and a quick ratio of 5.48. The stock has a market capitalization of $1.14 billion, a PE ratio of -10.65 and a beta of 0.15.

Uniqure (NASDAQ:QURE) last announced its earnings results on Monday, April 30th. The biotechnology company reported ($0.59) EPS for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.15. Uniqure had a negative net margin of 586.38% and a negative return on equity of 131.55%. The business had revenue of $3.48 million during the quarter, compared to analysts’ expectations of $3.08 million. sell-side analysts predict that Uniqure will post -2.88 EPS for the current year.

In other news, CEO Matthew C. Kapusta sold 39,169 shares of the business’s stock in a transaction dated Thursday, March 15th. The shares were sold at an average price of $21.72, for a total transaction of $850,750.68. Following the transaction, the chief executive officer now directly owns 439,764 shares in the company, valued at $9,551,674.08. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 0.73% of the company’s stock.

Several institutional investors have recently modified their holdings of QURE. Federated Investors Inc. PA acquired a new position in shares of Uniqure during the first quarter worth about $21,573,000. Millennium Management LLC grew its position in Uniqure by 242.8% during the first quarter. Millennium Management LLC now owns 759,585 shares of the biotechnology company’s stock worth $17,850,000 after buying an additional 538,031 shares during the period. Macquarie Group Ltd. grew its position in Uniqure by 660.1% during the fourth quarter. Macquarie Group Ltd. now owns 532,049 shares of the biotechnology company’s stock worth $10,423,000 after buying an additional 462,049 shares during the period. BlackRock Inc. grew its position in Uniqure by 999.6% during the fourth quarter. BlackRock Inc. now owns 468,422 shares of the biotechnology company’s stock worth $9,177,000 after buying an additional 425,823 shares during the period. Finally, RTW Investments LP acquired a new position in Uniqure during the fourth quarter worth about $7,905,000. Institutional investors and hedge funds own 36.74% of the company’s stock.

Uniqure Company Profile

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease.

Analyst Recommendations for Uniqure (NASDAQ:QURE)

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply